MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has entered into a distribution agreement with Zimmer, Inc. Through the agreement, MiMedx will provide its dehydrated human amnion/chorion membrane ("dHACM") allograft products to Zimmer to be marketed non- exclusively on a private label basis.
The MiMedx dHACM allografts, processed utilizing the Company's proprietary PURION® process, will be provided to Zimmer for marketing under Zimmer's private-label. Through-out the United States, Zimmer will market and sell the private-labeled allografts to Zimmer customers and end-users. The distribution agreement encompasses a range of musculoskeletal applications to include reconstructive, sports medicine, trauma, extremities and spinal applications.
Parker H. Petit, MiMedx Chairman and CEO, said, "We are very pleased about the opportunity to partner with Zimmer. This agreement will facilitate a sizable expansion of the physicians and patients that will now have access to our dHACM allografts. The breadth of the applications included in the agreement and the large base of physicians, hospitals and other medical facilities served by Zimmer will enhance the presence of our allografts in the musculoskeletal sector of the market."
"Zimmer has a stellar reputation and is a recognized leader in bringing new technologies and applications to the forefront to serve the reconstructive, sports medicine, trauma, extremities and spinal markets," said Bill Taylor, MiMedx President and COO. "Our goal is to reach as many patients as possible that will benefit from the regenerative properties of our allografts. Our relationship with Zimmer will allow us to further the realization of that goal."
Study shows large language models susceptible to misinformation